Cluster of differentiation 4-positive and cluster of differentiation 8-positive T lymphocytes (CD4+ and CD8+ T cells) (CD4+ and CD8+ T cells)

CD4+ and CD8+ T lymphocytes are the primary effector cells of the adaptive immune system, defined by the expression of specific surface glycoproteins that act as co-receptors for the T-cell receptor (TCR) (StatPearls: T-cell Lymphocytes, 2023). CD4+ T cells, or helper T cells, coordinate immune responses by secreting cytokines and activating other immune cells upon recognizing antigens presented by MHC class II molecules (NIH: HIV and CD4, 2023). CD8+ T cells, or cytotoxic T cells, directly identify and eliminate virally infected or malignant cells through the recognition of MHC class I-presented antigens (Nature Reviews Cancer: PD-1/PD-L1, 2020). These cells are critical therapeutic targets; they are the primary site of HIV infection and depletion, the focus of immunosuppressive therapy in transplantation and autoimmunity, and the targets of checkpoint inhibitors and CAR-T therapies in oncology (Mayo Clinic: Immunosuppressants, 2023). Pharmacological intervention can involve the inhibition of intracellular signaling to prevent proliferation, the blockade of inhibitory receptors to restore effector function, or the direct depletion of the cell population (PubChem: Cyclosporine, 2024).

Other names

Helper T cellsCytotoxic T cellsT-lymphocytesCD4+ cellsCD8+ cellsCD4+ and CD8+ T-lymphocytesEffector T cells

Drugs targeting these cells act by inhibiting calcineurin to prevent T-cell activation and IL-2 production (e.g., Cyclosporine), blocking immune checkpoints like PD-1 or CTLA-4 to restore anti-tumor effector function (e.g., Nivolumab, Ipilimumab), or directly binding to surface markers to deplete the cell population or modulate signaling (e.g., Muromonab-CD3, Alemtuzumab) (StatPearls: Immunosuppressants, 2023; Nature Reviews Cancer: PD-1/PD-L1, 2020).